Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $21.75.

VTYX has been the subject of a number of recent research reports. Wells Fargo & Company upgraded Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $7.00 to $16.00 in a research note on Tuesday, March 12th. Oppenheimer upgraded Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a research note on Tuesday, March 12th. Lifesci Capital upgraded Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research note on Wednesday, February 28th. Finally, Canaccord Genuity Group lowered their target price on Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th.

Ventyx Biosciences Price Performance

Ventyx Biosciences stock opened at $4.38 on Thursday. The stock’s 50-day moving average is $5.84 and its 200-day moving average is $6.70. The company has a market cap of $308.79 million, a price-to-earnings ratio of -1.33 and a beta of 0.27. Ventyx Biosciences has a 12 month low of $1.87 and a 12 month high of $40.58.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Tuesday, February 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.08. During the same period last year, the business posted ($0.62) earnings per share. Research analysts anticipate that Ventyx Biosciences will post -2.55 EPS for the current year.

Institutional Investors Weigh In On Ventyx Biosciences

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Ventyx Biosciences by 40.5% in the 4th quarter. Vanguard Group Inc. now owns 3,741,925 shares of the company’s stock worth $9,243,000 after acquiring an additional 1,079,254 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Ventyx Biosciences in the 4th quarter worth approximately $546,000. Sphera Funds Management LTD. acquired a new position in shares of Ventyx Biosciences in the 4th quarter worth approximately $445,000. Voloridge Investment Management LLC acquired a new position in shares of Ventyx Biosciences in the 4th quarter worth approximately $370,000. Finally, Occudo Quantitative Strategies LP acquired a new position in shares of Ventyx Biosciences in the 4th quarter worth approximately $729,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.